NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Maze Therapeutics, Inc. (MAZE) Stock Analysis

Maze Therapeutics, Inc. (MAZE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

MAZE

$32.58

+$0.13 (+0.40%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MAZE with… →

MAZE Key Statistics

As of Oct 21, 2026
Trading
Open
$32.52
Previous Close
$32.45
Day's Range
31.56–33.19
52-Week Range
21.95–53.65
Volume
1.07M
Valuation
Market Cap
$1.81B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
90.49
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.48
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$131.12M−351.04%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
55.55M
1-Year Return
+10.37%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
627.53K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, MAZE closed at $32.58, +10.37% over 1 year.

Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.81B.

In fiscal 2025, MAZE reported revenue of $0.00.

MAZE Stock Return by Calendar Year

Maze Therapeutics, Inc. (MAZE) return since Jan 2025: what $10,000 became

1 year
$10,000 $11,037
+10.37%
Since Jan 2025
$10,000 $20,426
+104.26%

If you had invested $10,000 in Maze Therapeutics, Inc. (MAZE) at the close on January 31, 2025, the earliest close on record here, it would have been worth $20,426 at the close on October 21, 2026: +104.26% in total, +51.50% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−21.36%
2025+159.75%

As of October 21, 2026.

MAZE Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$131.12M—
2024$167.50M$52.23M31.2%
2023$0.00−$100.42M—
2022$0.00−$114.94M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$142.90M−$131.12M—
2024$167.50M—$57.59M$52.23M31.2%
2023$0.00—−$98.55M−$100.42M—
2022$0.00—−$111.03M−$114.94M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MAZE Valuation vs Biotechnology Median

Median of 608 stocks
MetricMAZEBiotechnology medianvs median
P/S ratio90.4913.306.8x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 18 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Maze Therapeutics, Inc. (MAZE) at $1.81B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 141.

MAZE last closed at $32.58 on October 21, 2026. That is +$0.13 (+0.40%) against the previous close. Over the past 52 weeks the price has ranged from $21.95 to $53.65. The latest close sits 48.43% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. Against the prior fiscal year total of $167.50M, that is a change of −100.00%. The same year closed with a net loss of $131.12M. Trailing earnings per share are −2.48.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 90.49 times revenue. On price-to-sales that is 6.8 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +10.37%. The stored price history starts on January 31, 2025, and the total return since then is +104.26%. Daily returns over the trailing 1 year annualize to a volatility of 67.68%.

Growth & Income

The record shows no dividend for MAZE.

So far in 2026 the total return is −21.36%. The record holds one complete calendar year, 2025, which returned +159.75%.

Peer Comparison

Maze Therapeutics, Inc. (MAZE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Maze Therapeutics, Inc. MAZE $1.81B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Maze Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Maze Therapeutics, Inc.

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Visit website →